Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib
Encorafenib/binimetinib is a new combination BRAF/MEK inhibitor used in the treatment of advanced or metastatic BRAFV600-mutant melanoma. Though generally tolerated well, mild to moderate aminotransferase elevations are common. However, significant liver injury has not been demonstrated in the liter...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2019/3051945 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548347972419584 |
|---|---|
| author | Nicholas Gravbrot Srinath Sundararajan |
| author_facet | Nicholas Gravbrot Srinath Sundararajan |
| author_sort | Nicholas Gravbrot |
| collection | DOAJ |
| description | Encorafenib/binimetinib is a new combination BRAF/MEK inhibitor used in the treatment of advanced or metastatic BRAFV600-mutant melanoma. Though generally tolerated well, mild to moderate aminotransferase elevations are common. However, significant liver injury has not been demonstrated in the literature. Here, we report the first case of severe hepatic injury associated with encorafenib/binimetinib in a 58-year-old gentleman requiring admission and extensive workup. He was successfully treated by withdrawing the combination therapy, and liver function returned to normal range. |
| format | Article |
| id | doaj-art-bc72496630ff41c5a7062decc8bc1676 |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-bc72496630ff41c5a7062decc8bc16762025-02-03T06:14:17ZengWileyCase Reports in Oncological Medicine2090-67062090-67142019-01-01201910.1155/2019/30519453051945Severe Drug-Induced Liver Injury from Combination Encorafenib/BinimetinibNicholas Gravbrot0Srinath Sundararajan1Division of Hematology-Oncology, Department of Medicine, University of Arizona Cancer Center, Tucson, AZ, USADivision of Hematology-Oncology, Department of Medicine, University of Arizona Cancer Center, Tucson, AZ, USAEncorafenib/binimetinib is a new combination BRAF/MEK inhibitor used in the treatment of advanced or metastatic BRAFV600-mutant melanoma. Though generally tolerated well, mild to moderate aminotransferase elevations are common. However, significant liver injury has not been demonstrated in the literature. Here, we report the first case of severe hepatic injury associated with encorafenib/binimetinib in a 58-year-old gentleman requiring admission and extensive workup. He was successfully treated by withdrawing the combination therapy, and liver function returned to normal range.http://dx.doi.org/10.1155/2019/3051945 |
| spellingShingle | Nicholas Gravbrot Srinath Sundararajan Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib Case Reports in Oncological Medicine |
| title | Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib |
| title_full | Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib |
| title_fullStr | Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib |
| title_full_unstemmed | Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib |
| title_short | Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib |
| title_sort | severe drug induced liver injury from combination encorafenib binimetinib |
| url | http://dx.doi.org/10.1155/2019/3051945 |
| work_keys_str_mv | AT nicholasgravbrot severedruginducedliverinjuryfromcombinationencorafenibbinimetinib AT srinathsundararajan severedruginducedliverinjuryfromcombinationencorafenibbinimetinib |